06 Jan 2023 U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
06 Jan 2023 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
04 Jan 2023 Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
28 Dec 2022 U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
27 Dec 2022 BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
22 Dec 2022 BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
21 Dec 2022 Novel, personalized immunotherapy platform designed to achieve Trifecta of anti-cancer activity using unique bi-shRNA DNA-based plasmid and patient's own tumor tissue
21 Dec 2022 VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
20 Dec 2022 BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
15 Dec 2022 Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met
15 Dec 2022 Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
12 Dec 2022 Amphera Announces Clinical Updates of MesoPher Cell Therapy
09 Dec 2022 PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
08 Dec 2022 Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
07 Dec 2022 U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
05 Dec 2022 Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
01 Dec 2022 AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
30 Nov 2022 Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2
29 Nov 2022 Providence Therapeutics Presents Phase 2 Data on its mRNA COVID-19 Vaccine Candidate PTX-COVID19-B at the 2022 World Vaccine & Immunotherapy Congress
23 Nov 2022 Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
21 Nov 2022 Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
18 Nov 2022 INOVIO Provides an Update on Lassa Fever and MERS Programs
18 Nov 2022 Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
18 Nov 2022 Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
17 Nov 2022 Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up